Fusion, Derived From T(12,16) Malignant Liposarcoma (Human)
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-FUS antibody (Catalog #: ARP40278_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Purification
Purified
Indications d'application
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
Fusion, Derived From T(12,16) Malignant Liposarcoma (Human)
Sujet
FUS binds both single-stranded and double-stranded DNA and promotes ATP-independent annealing of complementary single-stranded DNAs and D-loop formation in superhelical double-stranded DNA. FUS may play a role in maintenance of genomic integrity.
Alias Symbols: FUS-CHOP, FUS1, TLS, ALS6, POMP75, HNRNPP2
Protein Interaction Partner: FUS,GRIN1,GRIN2D,ILF3,POLR2A,PRMT1,PTBP1,RELA,RXRA,SF1,SFPQ,SPI1,SRRM1,SRSF10,SRSF2,SRSF4,THRA,YBX1,ZMYM2,EIF6,ILF3,OTUB1,PRMT1,PTBP2,RELA,RXRA,SARNP,SF1,SPI1,SRRM1,SRSF10,THRA,USF2,YBX1,ZMYM2